drugset / Trial / NCT00334646

Cyclophosphamide Drug Interaction Study In Cancer Patients

NCT00334646

Phase 1 Terminated 25 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

This study is designed to evaluate the potential pharmacokinetic interaction between oral GW679769 and IV (intravenous) cyclophosphamide when administered to cancer patients.

Timeline

Start
2005-08-10
Primary completion
2009-10-14
Completion
2009-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Casopitant Small molecule 150 mg Oral
Subject Cyclophosphamide Other / unclassified 500 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 700 mg/m2 Intravenous